CORPORATE PRESENTATION JANUARY 2019 Our Vision: Beleave will - - PowerPoint PPT Presentation
OTCQX: BLEVF CNSX: BE CORPORATE PRESENTATION JANUARY 2019 Our Vision: Beleave will continue to be a leading, global, vertically-integrated cannabis company. We cultivate high-quality cannabis flower and extracts, and are developing
JANUARY 2019 OTCQX: BLEVF CNSX: BE
2
January 2019 Beleave Inc. www.beleave.com
OTCQX: BLEVF CNSX: BE
3
Product Development Built on Research
R&D Team focused on developing products to capitalize on concentrates and edibles when allowed in 2019 Proprietary extraction and processing techniques (patent pending) Collaboration with academic institutions
Production Capacity
Anticipated production facility footprint in excess
Industry leading yields Facilities will be strategically located across Canada and abroad
Retail Expansion
Retail channel providing province-wide access to Saskatchewan market Pre-qualified for retail locations in Manitoba Flagship store to be built at production facility in Ontario
Sales and Distribution
Current provincial supply agreements with access to
Canadian population Strategy to capitalize on international opportunities with agreements in supply South American and European markets Diversified brands in, development, able to serve large and niche markets alike
OTCQX: BLEVF CNSX: BE
Who We Are
January 2019 Beleave Inc. www.beleave.com
4
January 2019 Beleave Inc. www.beleave.com
OTCQX: BLEVF CNSX: BE
April 13 Beleave Receives Sales License from Health Canada May 10 Beleave Closes Acquisition of Medi-Green Cannabis Clinic Network June 21 Beleave Expands its Global Footprint into Colombia July 19 Beleave Accelerates its Recreational Distribution Strategy by Acquiring Seven Oaks August 21 Beleave Starts Receiving POs from Ontario, BC, and Manitoba September 6 Beleave Signs Agreement to Acquire Nearly 250,000 Square Feet of Greenhouse Space and 85 Acres of Land to Expand its Production Capabilities September 20 Beleave Announces Planned Indoor Growing Capacity in British Columbia August 30 Beleave Secures Prime Location for its First Saskatchewan Retail Store October 17 Recreational Cannabis is Legalized in Canada October 29 Beleave Expands into European Cannabis Market Fall/Winter 2019 London, Ontario Facility comes online with nearly 250,000 square feet of indoor and greenhouse space Summer 2020 The two BC facilities are completed, adding 173,000 square feet to growing capacity Fall 2019 Recreational market expands as commercially manufactured edibles, beverages, and concentrates are legalized
2018 and Beyond
Spring 2019 Hamilton, Ontario Facility Receives GMP/ISO Certification November 15 Beleave Announces Development of Cannabis-Infused Powder and Sugar Products for the Recreational Market
5
January 2019 Beleave Inc. www.beleave.com
OTCQX: BLEVF CNSX: BE
In the News
Beleave in the News Whether it’s a story on cannabis employers and entrepreneurs, or a live interview the morning recreational cannabis became legal in Canada, Beleave has had great newsworthy moments.
November 9, 2018
“Follow the Money Investors Group interviews Bojan Krasic, President & CFO of Beleave Inc.
October 17, 2018
Beleave invites CP24 cameras into their Hamilton facility for a tour and learn more about their operations the morning
September 12, 2018
“Touting London's proximity to highways and its large labour pool, a pot producer has bought up a greenhouse
August 31, 2018
“Are you experienced? Lloydminster marijuana retailer looking for 'qualified' workers.”
August 29, 2018
“B.C. government has begun to buy bud.”
August 23, 2018
“Growth on the horizon for licensed pot producers.”
June 30, 2017
“With a year to go and amid predictions of a looming supply shortage, Health Canada is scrambling to add capacity once the legalization floodgates swing open.”
May 10, 2017
“Marijuana startups get new funding from 'streaming' deals.”
March 25, 2017
“Hamilton is home to at least three major marijuana cultivators, among the 40 growers licensed by the federal government to grow pot for medicinal purposes.”
Hamilton, Ontario
The first property in the Beleave portfolio, the Hamilton facility continues to be the hub of operations for extraction, packaging, and distribution.
GMP Certification:
Expected in Spring 2019
ISO Certification:
Anticipated in early 2019 Certification will facilitate international distribution
Expansion:
Starting Fall 2019 Greenhouse: 80,000 sq ft Indoor: 6,000 sq ft
London, Ontario
250, 000 sq ft existing greenhouse to be retrofitted on an 85 acre property.
Phase 1
Starting Fall 2019 Indoor: 26,700 sq ft
Phase 2
Starting Fall 2019 Greenhouse: 36,700 sq ft
Phase 3
Starting Early 2020 Greenhouse: 174,950 sq ft Indoor: 5,700 sq ft
British Columbia
Ten indoor growing facilities jointly- designed by Beleave and Kannavis Biotech Corp., on a 50/50 operating expenditure and revenue partnership.
Phase 1
Starting Summer 2020 Indoor: Abbotsford 86,700 sq ft Indoor: Chilliwack 86,700 sq ft
6
January 2019 Beleave Inc. www.beleave.com
OTCQX: BLEVF CNSX: BE
Facilities: Expansion Phases
Sales and Distribution: Canada
7
Planned Retail Location Planned Recreational Online Sales
January 2019 Beleave Inc. www.beleave.com
OTCQX: BLEVF CNSX: BE Now
Countrywide 100% of Canada
Now
BC, MB, ON 55.1% of Canada
Fall 2019
+ AB, SK 69.8% of Canada
Early 2020
+ QB, NS, NB 97.5% of Canada
Mid 2020
+ YT, NT, NU, NL 99.59% of Canada
Today Beleave has access to over half of the Canadian recreational marketplace; that number is expected to soar to over 97% in 2020.
Provincial population percentages based on 2016 Canadian Census
OTCQX: BLEVF CNSX: BE
Sales and Distribution: South America
January 2019 Beleave Inc. www.beleave.com
South American Expansion
In June 2018, Beleave expanded its global footprint into South America by acquiring a majority share in Procannmed; fully licensed for the cultivation, production, extraction and distribution of both THC and CBD medical cannabis in Colombia.
8
9
OTCQX: BLEVF CNSX: BE
Sales and Distribution: Europe
January 2019 Beleave Inc. www.beleave.com
European Expansion
In October 2018, Beleave expanded its global footprint again*, this time to Europe, by partnering with Canymed who has applied to supply the German market with medical cannabis.
*Pending government approvals and GMP Certification
10
January 2019 Beleave Inc. www.beleave.com
OTCQX: BLEVF CNSX: BE
Market Overview
Conservative estimates from Health Canada predict that the size of the medical cannabis market will reach 450,000 patients in the next six years.
New opportunities are on the horizon for Canadian LPs to supply foreign medical markets as many South American and European nations lack domestic production capacity.
Recreational market in Canada is expected require cannabis production of over 900,000 kg annually to meet its estimated value of $8.7 billion in the next six years.
Many provinces will soon be, or already are, in the process of accepting applications for more point-of-sale locations, and retail distribution points are expected to grow substantially in 2019.
Impactful studies highlight the promise
neurological and degenerative diseases, and as a powerful weapon against the
Companies are committing R&D resources to develop a wide variety of new product
for edibles, concentrates, and beverage- based cannabis products in 2019.
Seven Oaks, Beleave Inc.’s recreational brand, has strong distribution and sales channels in place. Seven Oaks appeals to consumers, both conceptually and in the quality it invokes, attracting them to become repeat customers.
Beleave Kannabis, our medical label, is available nation-wide. In 2019, we are leveraging research and new technologies to create a suite of highly focused, proprietary medical products, with higher margins.
Medi-Green is a leading network of medical cannabis clinics with locations across Ontario and Quebec. Medi-Green currently has an active patient base of approximately 3,000 Health Canada registered patients.
Our long-term objective is clear; we provide a consistent, reliable and curated product to suit the needs of our customers. Our suite of targeted brands enables us to build loyalty and enthusiasm across the Beleave family.
First recreational store will open in Saskatchewan in the coming months, allowing for province-wide online sales. Also, Beleave has pre-qualified for stores in Manitoba and expects to open a retail location at its location in London, Ontario subject to government approval.
11
OTCQX: BLEVF CNSX: BE
Sales and Distribution: Our Brands
January 2019 Beleave Inc. www.beleave.com
x
Sales and Distribution: Our Products
12
January 2019 Beleave Inc. www.beleave.com
OTCQX: BLEVF CNSX: BE
CBD God Bud Gelatino Shishkaberry Ultra Sour Pink Kush San Fernando Valley Kush Cold Creek Kush
BELEAVE KANNABIS SEVEN OAKS
Beleave has secured genetics acquisition agreements for a broad range of cannabis seed varieties from diverse lineages. A total of 90 new varieties were selected to cover the entire spectrum of low, intermediate, and high THC and CBD profiles.
We use nano-encapsulation of active ingredients to enhance bioavailability. The final product offered to consumers will be a flexible, food- grade ingredient that delivers an accurate dose of THC and CBD when ingested orally, with speedy delivery.
Low water solubility of extracts or oils makes incorporating them into food products or beverages difficult and can lead to low bioavailability, poor shelf-life, and unpredictable dosing;
addresses and solves these problems.
R&D being conducted at Beleave's Hamilton facility stems from a patent application submitted by Dr. Chen and
Manufacturing and extraction will be scaled-up to industrial levels and moved to Beleave's London, Ontario facility in the future.
13
OTCQX: BLEVF CNSX: BE
Product Development
January 2019 Beleave Inc. www.beleave.com
14
OTCQX: BLEVF CNSX: BE
Risk Mitigation
January 2019 Beleave Inc. www.beleave.com
Consistent product quality is attained through constant monitoring and testing to ensure plants are free from chemicals, heavy metals and microbiological contaminants.
Integrated distribution channels make Beleave stronger, providing direct access to the markets we serve.
Global political changes to medicinal and recreational cannabis laws allow Beleave to capitalize on markets outside of Canada.
Authentic brand offerings that are targeted to clearly defined demographics with multiple price-points to reach broad customer profiles and build brand loyalty.
an evolutionary biologist with a strong history studying weedy and invasive plant evolution and currently possesses a federally issued Industrial Hemp Research License. She has previously worked on industrial C. sativa production problems including heritability, maternal effects, phenotypic plasticity and extraction protocols.
McMaster University, a University Scholar, and the Associate Chair of Research for Surgery. He was won numerous awards for contributions to research and evidence-based orthopaedics including the Order of Ontario, and the Kappa Delta award. Michael Rogers joined the Department of Food Science in 2014 after holding faculty positions at Rutgers University and the University of Saskatchewan and as the Center Director for the Gastrointestinal Physiology Center at New Jersey’s Institute of Food, Nutrition and Health. He studies molecular gels, self-assembly of nano-fibers and nanotechnology, focusing on delivery of bio-actives and the biophysics of digestion. Michael is also the department’s graduate coordinator for the M.Sc. thesis and Ph.D. programs.
LESLEY CAMPBELL, PH.D.
RYERSON UNIVERSITY
MOHIT BHANDARI, PH.D.
MCMASTER UNIVERSITY
MICHAEL ROGERS, MSC & PH.D.
GUELPH UNIVERSITY
Insert Logo
15
January 2019 Beleave Inc. www.beleave.com
OTCQX: BLEVF CNSX: BE
Collaborative Partners
As part of a multi-year agreement, Beleave and Niagara University have partnered to provide opportunities for job placements with graduates from the university’s cannabis program.
INTERNSHIP PROGRAM
NIAGARA UNIVERSITY
Meet the Team
16
January 2019 Beleave Inc. www.beleave.com
OTCQX: BLEVF CNSX: BE
Executive Chairman, Chief Operational Officer, Director Bill was an early mover in Canada’s cannabis sector and has contributed significantly to successfully navigating the regulatory framework to obtain a cannabis production and sales
specializing in evaluating opportunities and helping set strategic goals in business development.
CA, CPA, B.COMM, MBA Chief Executive Officer, Director Andrew offers significant retail, finance and information technology experience from previous executive roles at Canadian Tire, Petro-Canada, and Heart and Stroke Foundation. He has led sizeable organizations and successfully executed on major
become a fully integrated organization that will have a significant leadership position in the cannabis industry.
Chief Science Officer, Director Roger leads Beleave's science and innovation program and offers substantial experience in laboratory management (University of Toronto & Toronto University Health Network) and his PhD training in the area of neuroimmunology.
Chief Communications Officer Kevin brings extensive experience, with over 25 years in capital markets working within the financial services industry to provide oversight to the
capital markets initiatives. As Beleave prepares for exciting announcements in the next year, Kevin will provide valuable strategic guidance to support the our growth and development.
Meet the Team
17
January 2019 Beleave Inc. www.beleave.com
OTCQX: BLEVF CNSX: BE
MIM President, Chief Financial Officer, Director Bojan was responsible for leading strategy, business development, M&A transactions for Beleave. With well
Bojan offers wide ranging financial expertise built with Thomas Weisel Partners Canada Inc., Stifel Nicolaus Canada Inc., and later serving as CEO
member of public and private companies.
SVP, Regulatory Affairs General Counsel Grant is a lawyer with over 14 years of government and regulatory experience. Grant has led a number of public sector organizations providing significant organizational skills and corporate governance experience to draw on. His past positions have included senior roles at the Privy Council Office, the Attorney General’s Office (Ontario), and for US government implementing partners in
Beleave, and was instrumental in securing provincial supply agreements.
Director Mark is the President of M2PM Limited and has more than thirty years
development industries, and ten years dedicated to executive services for the project design, construction and delivery for a full spectrum of publicly procured infrastructure projects, including complex construction projects, including the SkyDome, Metro Hall, Sunnybrook Hospital and Princess Margaret Hospital, to name a few.
Director Mark is an experienced pharmaceutical executive offering more than 25 years with Fortune 100, NYSE listed, research-based pharmaceutical companies including Bristol-Myers Squibb, Merck and Pfizer.
18
January 2019 Beleave Inc. www.beleave.com
OTCQX: BLEVF CNSX: BE
Key Takeaways
EXECUTIVE CHAIRMAN 905 979 4835 BILL@BELEAVE.COM 19
January 2019 Beleave Inc. www.beleave.com
OTCQX: BLEVF CNSX: BE
Contact
CHIEF COMMUNICATIONS OFFICER 647 449 7352 KEVIN@BELEAVE.COM
This document includes forward-looking statements within the meaning of certain securities laws, including the “safe harbour” provisions of the
Securities Act (Ontario) and other provincial securities law in Canada. These forward-looking statements include, but are not limited to, statements with respect to our objectives, goals and strategies to achieve those objectives and goals, as well as statements with respect to our beliefs, plans,
“plan”, “anticipate”, “estimate”, “expect”, “intend”, “forecast”, “objective” and “continue” (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, which give rise to the possibility that predictions, forecasts, projections and other forward-looking statements will not be achieved. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. The Company strongly cautions readers not to place undue reliance on these statements, as a number of important factors, many of which are beyond our control, could cause the Company’s actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-look- ing statements. These factors include, but are not limited to: general economic conditions; pending and proposed legislative or regulatory developments in Canada including the impact of changes in laws, regulations and the enforcement thereof; reliance on funding models in Canada; operational and infrastructure risks including possible equipment failure and performance of information technology systems; intensify- ing competition resulting from established competitors and new entrants in the businesses in which the Company operates; insurance coverage of sufficient scope to satisfy any liability claims; fluctuations in total patients and customers; technological change and obsolescence; loss of services of key senior management personnel; privacy laws; structural subordination of common shares; leverage and restrictive covenants; fluctuations in cash timing and amount of capital expenditures; tax-related risks; unpredictability and volatility of the price of the Company’s securities; dilution; and future sales of the Company’s securities. The foregoing list of important factors that may affect future results is not exhaustive. When reviewing the Company’s forward- looking statements, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Except as required by Canadian securities law, the Company does not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by the Company or on the Company’s behalf. Such statements speak only as of the date made. The forward-looking statements contained in this Document should not be relied upon as represent- ing the view of the Company or its management as of any date subsequent to the date of this Document. Neither the Company nor its management is under any obligation, and neither undertakes, to update any of this information at any particular time. Neither the Company nor its management assumes any obligation to update or revise forward looking statements should circumstances or estimates
employees, agents or representatives makes any representation or warranty as to the accuracy or completeness of the Document or any statements, estimates or projections, and none will assume any liability for any representations (express or implied) contained in, or for any omissions from, the Document, or for any other written or oral communications transmitted to prospective investors in the course of their evaluation of the Company and its business. An investor will only be entitled to rely on those representations and warranties contained in the definitive agreement or agreements which constitute the financing. Use of this Document is restricted to parties to whom the Company delivers the Document and the recipient and its representatives shall keep confidential all information contained herein or otherwise provided in connection with the proposed financing which is not already public or which is not subsequently made public, and will use the Document only for the purpose set forth above. In addition, each recipient will not copy, reproduce or distribute the Document in whole or in part to others, at any time, without the prior express written consent of the Company.
20
OTCQX: BLEVF CNSX: BE
Disclaimer
January 2019 Beleave Inc. www.beleave.com